Evidence map›Paper›PMID 36627652›Full record

ArticleJournal of ovarian research2023

FOXD3 confers chemo-sensitivity in ovarian cancer through a miR-335/DAAM1/myosin II axis-dependent mechanism.

Shufen Wang, Yan Ma, Yi Hu, Xia Zhao, Yilin Li, Shuming Ouyang, Guifang Luo

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of ovarian research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Shufen WangThe First Affiliated Hospital, Department of Gynecology, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
Yan MaThe First Affiliated Hospital, Department of Gynecology, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
Yi HuThe First Affiliated Hospital, Department of Gynecology, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
Xia ZhaoThe First Affiliated Hospital, Department of Gynecology, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
Yilin LiThe First Affiliated Hospital, Department of Gynecology, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
Shuming OuyangThe First Affiliated Hospital, Reproductive Medicine Center, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China. 2021000019@usc.edu.cn.
Guifang LuoThe First Affiliated Hospital, Department of Gynecology, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China. 2021000018@usc.edu.cn.
University of South China · CNFirst Affiliated Hospital of University of South China · CN

Funding

Hunan Provincial Health Commission's Scientific Research Project in 2020 No. 20200479Hunan Provincial Health Commission's Scientific Research Project in 2020 No. 20201992
6 · The paper itself

Abstract

backgroundChemotherapy is among the most common treatment methods for ovarian cancer (OC). However, chemoresistance limits the effectiveness of chemotherapy and leads to treatment failure. We herein investigate the biological effect of forkhead box D3 (FOXD3) in the chemoresistance of OC cells.

methodsExpression of FOXD3, miR-335 and disheveled-associated activator of morphogenesis 1 (DAAM1) was detected in OC cells and tissues. The regulatory network of FOXD3/miR-335/DAAM1 was validated by dual-luciferase reporter and ChIP assays in vitro. After ectopic expression and depletion experiments in carboplatin/paclitaxel (CP)-resistant (A2780CP) or sensitive (A2780S) OC cells, cell viability, colony formation and apoptosis were tested by CCK-8 assay, colony formation assay and flow cytometry respectively. Effects of FOXD3 on the chemoresistance of OC cells in vivo were evaluated in OC xenografts in nude mice.

resultsOverexpression of FOXD3 impaired the proliferation and chemoresistance of OC cells, which was related to the promotion of the miR-335 expression. Functionally, DAAM1 was a putative target of miR-335. Silencing of DAAM1 was responsible for the inhibition of myosin II activation, consequently leading to suppressed OC cell proliferation and chemoresistance. In vivo results further showed that FOXD3 weakened the chemoresistance of OC cells to CP.

conclusionTaken together, we unveil a novel FOXD3/miR-335/DAAM1/myosin II axis that regulates the chemoresistance of OC both in vitro and in vivo.

Indexed as

Forkhead Transcription FactorsMicroRNAsOvarian NeoplasmsAnimalsCell Line, TumorCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansMiceMice, NudeMicrofilament ProteinsPaclitaxelrho GTP-Binding ProteinsDAAM1 protein, humanForkhead Transcription FactorsFOXD3 protein, humanMicrofilament ProteinsMicroRNAsMIRN335 microRNA, humanPaclitaxelrho GTP-Binding ProteinsChemoresistanceDAAM1FOXD3microRNA-335Myosin IIOvarian cancer

Identifiers

PMID36627652
PMCPMC9830800
OpenAlexW4313909613

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.